Letter: Filling the Gaps—Enhancing MASLD Prognosis With Imaging, Diverse Populations and Extended Follow‐Up. Authors' Reply DOI Open Access
Nobuharu Tamaki, Takefumi Kimura,

Shun‐ichi Wakabayashi

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(11-12), P. 1664 - 1665

Published: Oct. 28, 2024

In this study, we investigated whether the number of cardiometabolic criteria was associated with cardiovascular event risk and liver-related [1]. We found that while events increased criteria, no association observed between risk. Since diagnosis metabolic dysfunction-associated steatotic liver disease (MASLD) requires presence at least one criterion, our findings indicate need for further examination MASLD diagnostic criteria. As noted by Shen et al., a limitation Japan Medical Data Center (JMDC) database is lack imaging data [2]. relied on International Classification Diseases (ICD)-10 codes non-invasive steatosis markers. Although magnetic resonance elastography proton density fat fraction provide accurate assessments fibrosis hepatic content, their application in large populations presents significant challenges [3, 4]. While often diagnosed via ultrasound populations, has low sensitivity detecting mild [5, 6]. Furthermore, phenomenon 'burned-out', where decreases as progresses, well documented [7]. Consequently, ultrasound-based may introduce additional biases. Nonetheless, use ICD-10 markers diagnosing cohorts remains meaningful. acknowledge JMDC cohort predominantly consists relatively young males, which introduces bias. result, incidence rates are likely lower compared to higher-risk such elderly. Therefore, it essential evaluate relevance high-risk raise important questions regarding current Regarding follow-up period, there be some misunderstanding. analysis, examined average from first year observation through tenth year, an period 5.2 years. Thus, results reflect long-term changes clinical status were not strongly impact antidiabetic drugs glycaemic control beyond scope investigation [8], plan explore aspect future research. The authors' declarations personal financial interests unchanged those original article [Ref. 1]. Nobuharu Tamaki: conceptualization, writing – draft, review editing, funding acquisition. Takefumi Kimura: editing. Shun-Ichi Wakabayashi: Takeji Umemura: acquisition, supervision. Namiki Izumi: Rohit Loomba: supervision, Masayuki Kurosaki: Kurosaki receives support Agency Research Development (JP24fk0210123, JP24fk0210113) Ministry Health, Labour Welfare (23HC2001). Tamaki (JP24fk0210111, JP24fk0210104), (23HC2003, 23HC2002). Umemura (JP24fk0210125). Loomba NCATS (5UL1TR001442), NIDDK (U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, P30DK120515), NHLBI (P01HL147835) John C Martin Foundation (RP124). serves consultant Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 Takeda, Terns Pharmaceuticals Viking Therapeutics. RL stock options Sagimet biosciences. addition, his institution received research grants Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Galectin Hanmi, Janssen, Madrigal Sonic Incytes Pharmaceuticals. Co-founder LipoNexus Inc. other authors have conflicts interest declare. This linked al papers. To view these articles, visit https://doi.org/10.1111/apt.18205 https://doi.org/10.1111/apt.18338. sharing applicable datasets generated or analysed during study.

Language: Английский

Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management DOI Creative Commons
Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi

et al.

Exploration of Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging and rapidly growing health problem that currently affects more than one-third of the world general population two-thirds patients with obesity or type 2 diabetes. MASLD associated one cardio-metabolic risk factors (CMRFs) determine complexity its natural history management. Although term encompasses a single disease, each CMRF has different impact on MASLD, number overlapping CMRFs results in rate progression outcomes both systemic disease. Its pathogenesis characterized by insulin resistance, lipotoxicity complex cross-talk between liver, adipose tissue, muscle, intestine through release hepatokines, cytokines, myokines inflammatory products. The stage fibrosis best predictor outcomes, such as failure mortality, also predicts high all-cause mortality In many cases, development hepatocellular carcinoma (HCC) advanced cirrhosis, although it can occur at all stages making prevention difficult. increasing very low-density lipoprotein (VLDL) secretion chronic low-grade inflammation, which increase cardio-vascular, renal, endocrine diseases extrahepatic cancer. Thus, management requires holistic approach treatment multispecialty collaboration. Currently, diet physical activity are effective first-line approaches. There no approved drugs for apart from resmetirom, percentage cases improves metabolic steatohepatitis (MASH) fibrosis. We summarize wide varied recent literature etiopathogenetic, clinical therapeutic aspects connecting interpreting to facilitate

Language: Английский

Citations

0
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality DOI
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Characterising the phenotypic features of individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) can help identify high-risk subpopulations within this group. High-sensitivity troponin (hs-troponin) is a significant risk factor for future cardiovascular events. We studied association hs-troponin in absence all-cause and cause-specific mortality among MASLD. used National Health Nutrition Examination Survey 1999-2004 linked dataset through 2019. Cox regression models to assess between MASLD without disease. During median follow-up period 17.5 years (IQR: 15.9-19.1), higher levels T were associated progressively hazards mortality, which remained after adjustment demographic, clinical, lifestyle factors. There was 29% (hazard ratio [HR]: 1.29, 95% confidence interval [CI]: 1.16-1.44) increase 44% (HR: 1.44, CI: 1.20-1.72) every rise 1-standard deviation T. A (p trend) noted 3 I assays, similar no cancer-related mortality. Screening or at-risk group that have predominantly due disease-related population

Language: Английский

Citations

0
AI‐Based Platelet‐Independent Noninvasive Test for Liver Fibrosis in MASLD Patients DOI Creative Commons

Shun‐ichi Wakabayashi,

Takefumi Kimura,

Nobuharu Tamaki

et al.

JGH Open, Journal Year: 2025, Volume and Issue: 9(4)

Published: April 1, 2025

ABSTRACT Background and Aim Noninvasive tests (NITs), such as platelet‐based indices ultrasound/MRI elastography, are widely used to assess liver fibrosis in metabolic dysfunction‐associated steatotic disease (MASLD). However, platelet counts not routinely included Japanese health check‐ups, limiting their utility large‐scale screenings. Additionally, while effective, is costly less accessible routine practice. Most existing AI‐based models incorporate these markers, restricting applicability. This study aimed develop a simple yet accurate AI model for staging using only demographic biochemical markers. Methods retrospective analyzed biopsy‐proven data from 463 MASLD patients. Patients were randomly assigned training ( N = 370, 80%) test 93, 20%) cohorts. The incorporated age, sex, BMI, diabetes, hypertension, hyperlipidemia, blood markers (AST, ALT, γ‐GTP, HbA1c, glucose, triglycerides, cholesterol). Results Support Vector Machine demonstrated high diagnostic performance, with an area under the curve (AUC) of 0.886 detecting significant (≥ F2). AUCs advanced F3) cirrhosis (F4) 0.882 0.916, respectively. Compared FIB‐4, APRI, FAST score (0.80–0.96), SVM achieved comparable accuracy eliminating need count or elastography. Conclusion accurately assesses patients without requiring Its simplicity, cost‐effectiveness, strong performance make it well‐suited screenings clinical use.

Language: Английский

Citations

0
Deep Learning-Based Prediction Models for Liver-Related and Cardiovascular Events in Steatotic Liver Disease DOI

Shun‐ichi Wakabayashi,

Takefumi Kimura,

Nobuharu Tamaki

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
Editorial: Cardiometabolic criteria matters in MASLD DOI Open Access
Margaret Teng, Mark Muthiah, Daniel Q. Huang

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(8), P. 1126 - 1127

Published: Sept. 3, 2024

LINKED CONTENT This article is linked to Tamaki et al papers. To view these articles, visit https://doi.org/10.1111/apt.18205 and https://doi.org/10.1111/apt.18243

Language: Английский

Citations

1
Letter: Filling the Gaps—Enhancing MASLD Prognosis With Imaging, Diverse Populations and Extended Follow‐Up DOI

Qi‐En Shen,

Chengfu Xu

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(11-12), P. 1662 - 1663

Published: Oct. 28, 2024

The authors have nothing to report.

Language: Английский

Citations

1
Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinemia DOI Open Access
Nakul J. Bhardwaj,

Rebecca G. Kim

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 30, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent, chronic condition. It linked to variety of cardiometabolic risk factors, such as obesity and type 2 diabetes [1]. Its identification challenging due its asymptomatic nature, wide spectrum phenotypes (isolated steatosis cirrhosis) lack specific diagnostic markers. Although there are several noninvasive scores models assess the severity MASLD, few markers that help identify Many patients with MASLD have enzymes within normal range, leading further delays in diagnosis. Elevated serum ferritin has been associated increased fibrosis worse clinical outcomes MASLD. Hyperferritinemia can result from systemic inflammation iron stores, which both common Prior studies, fact, shown higher levels correlate severity, liver-related events, all-cause mortality histological findings, including steatosis, hepatocellular ballooning [2-4]. Finally, odds fibrosis, suggesting could potentially serve useful biomarker for assessing progression [5, 6]. link between MASLD/hepatic identified, prevalence among hyperferritinemia remains unclear. The piece by Amangurbanova et al. evaluates significant [7]. This cross-sectional, prospective cohort study conducted San Diego, California 2016 2023, examined 523 adults (50–80 years old) diabetes. Participants were excluded if they had evidence other than previously known cirrhosis, prior gastrointestinal bypass surgery or use producing medications. utilised imaging fibrosis. findings supported high predict In their cohort, approximately 80% those found More third these hepatic Findings this support notion may be There are, however, limitations consider. occurs conditions, inflammation, infection, malignancy diseases [8]. Thus, reducing specificity addition, insulin resistance metabolic syndrome, confound interpretation levels, irregularities secondary dysfunction, rather genetic variants influence progression, adds overall complexity using predictive marker [6]. Ultimately, an important prognostic factor [9], al., highlight potential utility Nakul J. Bhardwaj: writing – original draft, review editing. Rebecca G. Kim: editing, supervision. article al papers. To view articles, visit https://doi.org/10.1111/apt.18377 https://doi.org/10.1111/apt.18470. Data sharing not applicable no datasets generated analysed during current study.

Language: Английский

Citations

1
Editorial: Cardiometabolic criteria matters in MASLD—Authors' reply DOI
Nobuharu Tamaki, Takefumi Kimura,

Shun‐ichi Wakabayashi

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(8), P. 1128 - 1129

Published: Sept. 3, 2024

LINKED CONTENT This article is linked to Tamaki et al papers. To view these articles, visit https://doi.org/10.1111/apt.18205 and https://doi.org/10.1111/apt.18233

Language: Английский

Citations

0
Letter: Filling the Gaps—Enhancing MASLD Prognosis With Imaging, Diverse Populations and Extended Follow‐Up. Authors' Reply DOI Open Access
Nobuharu Tamaki, Takefumi Kimura,

Shun‐ichi Wakabayashi

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(11-12), P. 1664 - 1665

Published: Oct. 28, 2024

In this study, we investigated whether the number of cardiometabolic criteria was associated with cardiovascular event risk and liver-related [1]. We found that while events increased criteria, no association observed between risk. Since diagnosis metabolic dysfunction-associated steatotic liver disease (MASLD) requires presence at least one criterion, our findings indicate need for further examination MASLD diagnostic criteria. As noted by Shen et al., a limitation Japan Medical Data Center (JMDC) database is lack imaging data [2]. relied on International Classification Diseases (ICD)-10 codes non-invasive steatosis markers. Although magnetic resonance elastography proton density fat fraction provide accurate assessments fibrosis hepatic content, their application in large populations presents significant challenges [3, 4]. While often diagnosed via ultrasound populations, has low sensitivity detecting mild [5, 6]. Furthermore, phenomenon 'burned-out', where decreases as progresses, well documented [7]. Consequently, ultrasound-based may introduce additional biases. Nonetheless, use ICD-10 markers diagnosing cohorts remains meaningful. acknowledge JMDC cohort predominantly consists relatively young males, which introduces bias. result, incidence rates are likely lower compared to higher-risk such elderly. Therefore, it essential evaluate relevance high-risk raise important questions regarding current Regarding follow-up period, there be some misunderstanding. analysis, examined average from first year observation through tenth year, an period 5.2 years. Thus, results reflect long-term changes clinical status were not strongly impact antidiabetic drugs glycaemic control beyond scope investigation [8], plan explore aspect future research. The authors' declarations personal financial interests unchanged those original article [Ref. 1]. Nobuharu Tamaki: conceptualization, writing – draft, review editing, funding acquisition. Takefumi Kimura: editing. Shun-Ichi Wakabayashi: Takeji Umemura: acquisition, supervision. Namiki Izumi: Rohit Loomba: supervision, Masayuki Kurosaki: Kurosaki receives support Agency Research Development (JP24fk0210123, JP24fk0210113) Ministry Health, Labour Welfare (23HC2001). Tamaki (JP24fk0210111, JP24fk0210104), (23HC2003, 23HC2002). Umemura (JP24fk0210125). Loomba NCATS (5UL1TR001442), NIDDK (U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, P30DK120515), NHLBI (P01HL147835) John C Martin Foundation (RP124). serves consultant Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 Takeda, Terns Pharmaceuticals Viking Therapeutics. RL stock options Sagimet biosciences. addition, his institution received research grants Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Galectin Hanmi, Janssen, Madrigal Sonic Incytes Pharmaceuticals. Co-founder LipoNexus Inc. other authors have conflicts interest declare. This linked al papers. To view these articles, visit https://doi.org/10.1111/apt.18205 https://doi.org/10.1111/apt.18338. sharing applicable datasets generated or analysed during study.

Language: Английский

Citations

0